Susan E. Cellitti
Novartis
4 Papers
123 Citations
Susan E. Cellitti is an academic researcher from Novartis. The author has contributed to research in topics: Pyrrolysine & Mycobacterium tuberculosis. The author has an hindex of 4, co-authored 4 publications.
Chat about Author
Papers
Patent
Dual function proteins for treating metabolic disorders
Brian R. Boettcher,Shari L. Caplan,Susan E. Cellitti,Douglas S. Daniels,Norio Hamamatsu,Bernhard H. Geierstanger,Stuart Licht,Andreas Loew,Stephen Craig Weldon +8 more
- 26 Sep 2012
TL;DR: In this paper, the identification of new proteins comprising fibroblast growth factor 21 (FGF21) and other metabolic regulators, including variants thereof, known to improve metabolic profiles in subjects to whom they are administered.
84
Patent
Biosynthetically generated pyrroline-carboxy-lysine and site specific protein modifications via chemical derivatization of pyrroline-carboxy-lysine and pyrrolysine residues
Bernhard H. Geierstanger,Weijia Ou,Susan E. Cellitti,Tetsuo Uno,Tiffany Crossgrove,Hsien-Po Chiu,Jan Grünewald,Xueshi Hao +7 more
- 23 Oct 2009
TL;DR: In this paper, pyrroline-carboxy-lysine (PCL) is presented as a natural, biosynthetically generated amino acid, and methods for synthesizing PCL are presented.
22
Erratum: Structure of DDn, the deazaflavin-dependent nitroreductase from mycobacterium tuberculosis involved in bioreductive activation of PA-824 (Structure (2012) 20 (101-112))
Susan E. Cellitti,Jennifer Shaffer,David H. Jones,Tathagata Mukherjee,Meera Gurumurthy,Badry Bursulaya,Helena I. Boshoff,Inhee Choi,Amit Nayyar,Yong Sok Lee,Joseph Cherian,Pornwaratt Niyomrattanakit,Thomas Dick,Ujjini H. Manjunatha,Clifton E. Barry,Glen Spraggon,Bernhard H. Geierstanger +16 more
TL;DR: This work presents a novel and scalable approach called “cell reprograming” that allows for real-time annotation of the response of the immune system to tuberculosis.
12
Patent
Antibody drug conjugates for ablating hematopoietic stem cells
Ben Wen,Anthony E. Boitano,Burger Matthew,Susan E. Cellitti,Michael P. Cooke,Finner Catrin,Bernhard H. Geierstanger,Yunho Jin,Si Tuen Lee-Hoeflich,Pham Hongngoc Thi,Siew Ho Schleyer,Tissot Kathrin,Tetsuo Uno +12 more
- 19 Dec 2017
TL;DR: In this paper, an antibody or antibody fragment that specifically binds to human cKIT is linked to a drug moiety, optionally through a linker, and methods of making and using such pharmaceutical compositions for ablating hematopoietic stem cells in a patient in need thereof.
6